Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

[1]  M M Regan,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  E. Winer,et al.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  T. Whelan,et al.  Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Neven,et al.  Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Whelan,et al.  Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. , 2016, The New England journal of medicine.

[6]  T. Julian,et al.  Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial , 2016, The Lancet.

[7]  R. Gelber,et al.  Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. , 2015, The Lancet. Oncology.

[8]  R. Coombes,et al.  Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation , 2012, British Journal of Cancer.

[9]  L. Terhorst,et al.  Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy , 2011, Psycho-oncology.

[10]  A. Brodie,et al.  Stopping treatment can reverse acquired resistance to letrozole. , 2008, Cancer research.

[11]  D. Cella,et al.  Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women , 2008, Breast Cancer Research and Treatment.

[12]  J. Forbes,et al.  Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Cuzick,et al.  Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer , 2006, Breast Cancer Research and Treatment.

[14]  T. Whelan,et al.  Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Ganz,et al.  The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. , 2005, Journal of the National Cancer Institute.

[16]  J. Sloan,et al.  Issues for Statisticians in Conducting Analyses and Translating Results for Quality of Life End Points in Clinical Trials , 2004, Journal of biopharmaceutical statistics.

[17]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[18]  D. Cella,et al.  Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening , 2002, Quality of Life Research.

[19]  M Sullivan,et al.  Clinical relevance of single item quality of life indicators in cancer clinical trials , 2001, British Journal of Cancer.

[20]  P. Ganz,et al.  Life after breast cancer: understanding women's health-related quality of life and sexual functioning. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Gelber,et al.  Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The International Breast Cancer Study Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Forbes,et al.  Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer , 1996, The Lancet.

[23]  R. Gelber,et al.  Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trial. , 1996, Medical care.

[24]  A. Goldhirsch,et al.  The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials , 1993, Supportive Care in Cancer.

[25]  P. Butow,et al.  On the receiving end. IV: Validation of quality of life indicators. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  P. Neven,et al.  Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[27]  J. Bernhard,et al.  Patients' estimation of overall treatment burden: why not ask the obvious? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.